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Background: INR (International Normalized Ratio) is the biological reference test for the monitoring of vitamin K
antagonist (VKA) therapy. Overdosage of VKAs causes about 17,000 hospitalizations and 5,000 deaths each year in
France. To avoid these complications, monitoring and blood sampling conditions must be rigorous. In France, more
than half of INRs are carried out at home. The aim was to determine blood-sampling conditions at home, transit
time and the quality of the laboratory reagents used.
Method: Questionnaire-based, descriptive epidemiological cross-sectional prevalence study involving home care
nurses, family physicians (FPs) and clinical laboratories. Setting: Brittany, France, 2008. Study of the pre-analytical
phase of INRs sampled at home and its influence on INR results.
Results: The study included 291 FPs, 249 home care nurses, and 49 laboratories. 32.5% of reported INRs were
outside the therapeutic range. Samples were drawn into unsuitable tubes in 5.5% of cases and delivered in a
chilled condition in 9% of cases. In urban areas 50% of the tubes took more than 2 hours to reach the laboratory
compared with 71% from rural areas. The average International Sensitivity Index (ISI) of the thromboplastin was
1.62. The INRs provided by the laboratories were not analyzable in 64.7% of cases where blood samples had been
taken at home.
Conclusion: Blood sample quality, transit time and the reagents used are currently inadequate. The majority of INRs
taken at home are not reliable. FPs should consider these drawbacks in comparison with alternative solutions to
increase patient safety.Background
Vitamin K antagonists have been taken orally for more
than 40 years to ensure anticoagulation. Their main in-
dications are venous thromboembolism, artificial heart
valves and atrial fibrillation. The increasing prevalence
of cardiovascular illnesses in an aging population across
Europe and all developed countries means that the* Correspondence: lereste@univ-brest.fr
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stated.number of patients continues to increase [1] with about
900,000 patients currently receiving VKAs in France
alone [2].
Even where results show benefits for the patient, the
risk of hemorrhage and stroke remains an important
consideration. In 2007, VKAs were responsible for
17,000 hospitalizations and between 4,000 and 5,000
deaths [3] in France. In the DREES [2] (hospital-based)
study, just over 30% of serious, adverse outcomes linked
to medication, were due to an anticoagulant. Irregularity
in the supply of vitamin K causes an imprecise balancel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Le Reste et al. BMC Cardiovascular Disorders 2013, 13:71 Page 2 of 6
http://www.biomedcentral.com/1471-2261/13/71in the anticoagulation provided. Frequent blood testing is
therefore essential, bearing in mind the risk of under- or
over-dosage which could lead to thrombosis or bleeding.
When VKAs were first used, the monitoring was
conducted using Prothrombin Time (PT) measurement,
that is, the coagulation time for citrated blood plasma
when in contact with a reagent known as calcic throm-
boplastin. Thromboplastin is a tissue factor which acce-
lerates the process of coagulation. The use of PT in the
biological monitoring of treatment has been replaced by
the INR (International Normalized Ratio). This shows
the ratio (patient PT/control PT) raised to the ISI power
(International Sensitivity Index). The ISI reflects the sen-
sitivity of the thromboplastin to the reduction in vitamin
K dependent factors. In this mathematical formula, with
the ISI being the exponent, the higher the thrombo-
plastin ISI level, the greater the likelihood of mistakes in
determining the PT and the higher the rate of error in
calculating the INR.
Furthermore, the PT value is influenced by blood-
sampling conditions and it is essential that certain sam-
pling conditions are observed. The blood must be taken
cleanly, preferably without a tourniquet, and collected in
a tube containing citrate [4,5]. The tube must be reaso-
nably full with, ideally, 9 parts blood to 1 part citrate. It
must be turned upright smoothly without shaking the
contents. Each tube must be subjected to centrifugation.
Ideally, this should take place immediately after the
blood has been drawn; it can then be stored for up to
4 hours before analysis. The centrifugation may be post-
poned for up to 2 hours, after which the analysis should
be performed rapidly. Finally, the sample must be stored
at an ambient temperature prior to analysis and must,
under no circumstances, be chilled.
All these so-called pre-analytical conditions are nor-
mally well understood by analysis laboratories and that
is why patients are recommended, wherever possible, to
have their blood drawn at the laboratory. The INRs
drawn at home represent 48% to 66% of all blood sam-
ples taken in France [6]. In daily practice, INR follow-up
care is undertaken by Family Physicians (FPs). Other
procedures, such as blood-drawing at a Family Physi-
cian’s office or self-measuring are not available in France,
nor in many other European countries.
In 2006, for a thesis on family practice [7], a survey
was conducted amongst FPs, biologists and home care
nurses in one county in Brittany, on the practices in-
volved in administering VKAs. This was the first French
study of INR sampling conditions, at home, by home
care nurses. The survey shows numerous incidences of
incorrect tubes being used or samples being stored in
chilled conditions. In addition, the transit time generally
exceeded 2 hours, particularly in rural but also in urban
areas. Finally, the thromboplastin used by the laboratories,had ISI values which were too high. These results led to
doubts about the reliability of the INR obtained. The rela-
tively restricted sample of professionals questioned and
the limited geographic zone did not allow generalization.
The aim of this work was to identify INR sampling
conditions at home, in Brittany, in order to gauge the
reliability of the INR results obtained.
Method
This study is a descriptive cross-sectional epidemio-
logical prevalence study, to evaluate the practices of FPs,
home care nurses and laboratory biologists using a spe-
cific questionnaire for each profession. The distribution
and collection of the questionnaires took place between
January and March 2008 in the four counties of Brittany.
All FPs and home care nurses from Brittany were
selected from the ADELI directories of the Regional
Directorate for Health and Social Work covering urban
and rural areas. Exclusion criteria for FPs: those whose
practiced homeopathy, acupuncture or osteopathy as
their main activity. For nurses, there were no exclusion
criteria. Systematic randomization was undertaken, se-
lecting 1 in every 3 FPs and 1 in every 5 nurses. All the
medical analysis laboratories in those geographical areas
were included in the study.
Questionnaires
Each of the categories of professional received a question-
naire adapted to his/her practice (see Additional file 1).
The first part concerned the socio-professional context
and the second covered the practices relating to the bio-
logical monitoring of the VKA treatment.
One of the questions for the FPs and the nurses distin-
guished between types of practice environment: rural or
urban. This feature enabled the differentiation of transit
time according to practice environment.
All questionnaires had been tested in a pilot study.
That study was undertaken to ensure there were no mis-
understandings and no reversals of meaning due to
sentence-structure.
The questionnaires were anonymous. They were sent
by post with a letter explaining the study and a pre-paid
envelope for their return. Participation was completely
voluntary in every case.
Even though there was no patient involvement, the
promoters of the study asked for an Ethical Committee
Agreement. The Ethical Committee of the “Université
de Bretagne Occidentale” (Brest, France) accepted the
project.
Results
The response rates were upper than 30% for every popu-
lation and is described in Table 1.
Table 1 Response rate
Recipients FPs Nurses Biologists
Questionnaires Distributed 851 749 93
Returned 294 249 49
Completed 291 249 49
Response rate 33.8% 32.4% 52.7%
All response rates were upper than 30%.
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described in Table 2.
Nurse blood sampling conditions
5.5% of the nurses stated that they used non-citrate
tubes (heparinized or EDTA) and 9% transported the
tubes in chilled containers.
Nurse blood sampling and transit times
The number of nurses whose stated practices did not
conform to the recommendations was 64.7% (non-citrate
tubes, transportation in chilled containers and transit
times of > 2 hours). All transit times for both urban and
rural practices are listed in Table 3.
ISI values
In the laboratories, the ISI of the thromboplastins used
to calculate the INRs had an average value of 1.62 ± 0.21;
CI 95 = 1.21-2.02.
Quality control
All the laboratories which responded stated that they
ran daily in-house tests to check the variability of the
results and 15% stated that they never ran external tests
(i.e. between laboratories).
Discussion
Summary of main findings
The study of INR sampling conditions, at home, by
nurses has shown the use of tubes which were inap-
propriate in certain instances (which is a major failing);
transportation in chilled condition in other instances
(which is an important failing) and analysis outside the
time limit in the majority of cases (which is another im-
portant failing). These problems affected around 2 out
of 3 samples taken.
As expected, the transit time results show a clear dif-
ference between urban and rural areas. However, the
pooling of resources between laboratories is widespread
in large urban centers, with samples deposited at theTable 2 INR observed target values
Total INRs recorded INR rate 2-3 INR rate <2 INR
1224 58.5% 15.7% 2
More than one third of values were outside the therapeutic range.laboratory and only later sent for specialized technical
analysis. This lengthens the actual transit time and re-
duces the rural/urban difference observed in this study.
Furthermore, the biologists who responded used throm-
boplastins which had an average ISI value of 1.62. During
the calculation of the INR, these values increase the mis-
leading PT variations from the pre-analytical stages (which
is an important failing). Can we trust INR results from
samples taken at home? The actual consequences of the
gap between the INR obtained and the INR normally
expected could be analyzed in studies that modify each of
the individual parameters. Studies such as these exist [8,9]
but they used high quality thromboplastins, with an ISI
close to 1, which do not increase the errors in the pre-
analytical phase. Other studies would, of necessity, have to
be undertaken with higher ISI values.
The ‘external’ quality control tests compared the INR
results for the same plasma between different laborato-
ries. The variability obtained is usually between 12% and
15% in optimal, pre-analytical conditions. As the current
study has found pre-analytical conditions that fall far
short of the required standard, tests such as these, with
samples taken at home, should logically show greater
variability. Surely the iatrogenic effects, due to VKA, are
at least partially linked to the problem raised in this
study of sampling practices.
Comparison with existing literature
As a comparison, the team undertook a search of exis-
ting research literature. They found that research papers
have mainly compared ideal pre-analytical sampling con-
ditions in primary care clinics, in INR clinics, as well as
the use of self-assessment and computerized decision-
support systems, with conditions in university hospital
laboratories [10,11]. From these comparisons it has been
concluded that INR results from any of these sources
are safe and reliable. However, to our knowledge, no
other pragmatic study has been undertaken which is able
to show that INRs, sampled under current health-care
conditions, at some distance from a laboratory, were
either safe or reliable.
Questions and considerations for clinical practice and
future research
Health authorities have already disseminated infor-
mation in campaigns to remind professionals of good
practice in dealing with VKAs [12]. New information
that is better targeted and better disseminated might
avoid mistakes with the tubes or with the conditions ofrate >3 INR 3–4.5 INR rate outside therapeutic range
5.8% 9% 32.5% (estimated)
Table 3 Transit times*
District nurses Number in survey Average transit time for samples in minutes Samples with a transit time >120 minutes
Urban practice 169 110 ± 55 51%
Rural practice 80 181 ± 68 71%
(* Time necessary to transport the sample from home to laboratory).
51% of samples in urban practices and 71% in rural practices were delivered with a non-acceptable transit time.
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mains. With their current level of pay and workload,
would it really be reasonable to insist that nurses make a
return journey to the laboratory after each sample has
been taken, especially in rural areas? One possible solu-
tion would be to insist that laboratories employ more
couriers, with the aim of delivering each sample within a
maximum of 90 minutes, allowing the laboratories to
receive and to process the sample within the time limit
required. Making this available would incur additional
costs for the laboratory which they might have to
recover through their INR invoicing. This seems unlikely
in the current economic climate of budget restrictions.
Another possibility would be to encourage biologists
to use thromboplastins which have a lower ISI and
values of around 1. In this way, errors in the PT calcula-
tion would not be increased when calculating the INR.
However, certain technical constraints which hinder this
solution need to be clarified. An ISI close to 1 is not
ideal at the start of treatment, when the prothrombin
level is still raised, as the INR does not reflect the degree
of anticoagulation effectively. Currently, it is still recom-
mended that biologists use thromboplastins with an ISI
close to 1.5. However, these recommendations do not
take into consideration the results of this study on the
pre-analytical errors which occurred when samples were
taken at home. In addition, the choice of thromboplastin
and its ISI depends on the technical features of the
equipment used in the laboratory. The biologist is there-
fore dependent on the manufacturer of the technical
equipment, which often commercializes the use of a par-
ticular thromboplastin; consequently, this is another
unsuitable alternative.
Possible alternatives present themselves with the re-
cent appearance of new measuring devices [13] and new
oral anticoagulants [14].
The new measuring devices could be used at home by
the patient (if he is able) or be monitored by a nurse or
an FP. However the time allocation for nurses or FPs
would remain at a high level [15]. In addition, in many
countries the laboratories would take industrial action to
protest against loss of employment.
The new oral anticoagulant, belonging to the class of
non-peptide thrombin inhibitors, heralds a new era in
anticoagulation: one which will no longer require bio-
logical monitoring. Trials are under way to validate these
products in the treatment of atrial fibrillation [14,16]and thromboembolism [17]. Early findings of these non-
inferiority trials indicated a potential increase in patient
safety using these new anticoagulants (compared with
warfarin) [16] whilst, at the same time, being potentially
more effective for stroke prevention in atrial fibrillation.
If these indications are confirmed, it is highly likely that
FPs will be tempted to transfer rapidly to this new class
of anticoagulant in order to increase patient safety.
Strengths and limitations of the study
The 3 groups of professionals questioned were not rep-
resentative of the body of professionals practicing in
France. There is a selection bias in favor of rural areas.
For example, the urban/rural ratio for FPs was 70:30 in
this study (representative of Brittany) whereas it was
81:19 in mainland France in 2006.
A further example of selection bias is present for
nurses. The geographical area studied is not representa-
tive of France as there is unequal provision of nurses in
different regions. Brittany is situated in a well-equipped
area compared with the national average. A study [18]
using the same method took place in the Midi Pyrenees
region in 2008. This region is ranked 4th in metropolitan
France, in terms of home care nursing provision and
higher than Brittany. The average transit time limits
were shorter than 36 minutes, whether in urban or rural
areas. If the transit time limits are correlated effectively
at this level of provision, the results could be applied to
other French regions, however, there would, no doubt,
be other factors to take into consideration.
This study is subject to the biases which are inherent
in any survey by questionnaire.
Selection bias: The response level of approximately
one half, in the case of the analysis laboratories, and
more than one third, in the case of the nurses and FPs
selected, is reasonably good for this type of survey. How-
ever, despite randomization, the professionals who had
agreed to respond were self-selected, either by availabil-
ity or through their interest in the subject. Consequently,
it is probable that these professionals have greater know-
ledge in this field which, in turn, reduces the proportion
of errors observed when compared with actual practice.
Statement bias: this concerns the self-evaluation of prac-
tices undertaken by the professionals who responded. This
evaluation cannot be completely objective. Generally the
stated practices tend to be idealized, masking errors to
some extent, whether consciously or otherwise. In
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never completely removed by anonymity.
Conclusion
It is possible to generalize from our results and apply
them to most rural areas in Europe and to all health
systems where samples are subjected to a long transit
time. INRs taken at home do not meet pre-analytical
sampling requirements in over half of cases. Laborator-
ies are using Thromboplastin with a high ISI which mag-
nifies the pre-analytical errors. These dysfunctions offer
plausible explanations for part of the iatrogenic effects
linked to VKAs.
Any feasible improvements appear to be almost
impossible within the current structure of the French
health system where tests are, in the majority of cases,
completed after long transit times and for the most deli-
cate patients (those in care facilities, nursed at home or
bedridden). It is possible to generalize and apply these
findings to most rural areas in Europe in the current
economic climate of budget restrictions.
An innovative option could be to supply portable self-
measuring devices to be used at home, by the patient, if
possible. As an alternative, where necessary, measurement
could be undertaken by a nurse or an FP. Another innova-
tive option would be to replace VKAs with one of the new
classes of anticoagulant, which does not require a bio-
logical test, once the indication for the patient has been
validated and the possible incompatibilities evaluated.
Whilst awaiting these developments, the first recom-
mendation is that patients are encouraged to have their
INR blood samples drawn at the laboratory. For patients
who cannot travel, nurses should be advised to draw the
INR samples at the end of their round, or ensure that
the samples reach the laboratory rapidly. FPs should take
all these drawbacks into account before making a
decision.Additional file
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